Literature DB >> 1786633

Biology of tumors of the peripheral nervous system.

G M Brodeur1, J F Moley.   

Abstract

Tumors of the peripheral nervous system include neuroblastomas, pheochromocytomas, and neuroepitheliomas. Neuroblastomas and pheochromocytomas are adrenergic in origin and share certain genetic features, whereas neuroepitheliomas are thought to be cholinergic and are characterized by distinct genetic features. Neuroblastomas are characterized by deletion of the short arm of chromosome 1 (1p), amplification of the MYCN proto-oncogene, and hyperdiploidy in subsets of tumors. All three of these genetic features have prognostic value in subsets of patients. Allelic loss of 14q also occurs with increased frequency, but the prognostic importance of this abnormality is not known yet. Pheochromocytomas have not been studied as extensively, but allelic loss for 1p appears to be a frequent change, and no clear examples of oncogene activation have been identified to date. Neuroepitheliomas are characterized by translocation between chromosomes 11 and 22. Although they have a characteristic pattern of proto-oncogene expression, it is not clear that any of these oncogenes are activated specifically, and no sites of allelic loss have been identified to date. Thus, cytogenetic and molecular analysis of neuroblastomas, pheochromocytomas, and neuroepitheliomas are useful in distinguishing them from each other and from other tumors in selected cases. Furthermore, certain genetic markers are useful in predicting clinical behavior, especially for neuroblastoma.

Entities:  

Mesh:

Year:  1991        PMID: 1786633     DOI: 10.1007/bf00554794

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  82 in total

1.  Structure and activation of the human N-ras gene.

Authors:  E Taparowsky; K Shimizu; M Goldfarb; M Wigler
Journal:  Cell       Date:  1983-09       Impact factor: 41.582

2.  The c-sis oncogene is not activated in Ewing's sarcoma.

Authors:  J M Bechet; G Bornkamm; U K Freese; G M Lenoir
Journal:  N Engl J Med       Date:  1984-02-09       Impact factor: 91.245

3.  Chromosomal aberrations in human neuroblastomas.

Authors:  G M Brodeur; G Sekhon; M N Goldstein
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

4.  Chromosome findings and prognosis in 15 patients with neuroblastoma found by VMA mass screening.

Authors:  Y Hayashi; T Inaba; R Hanada; K Yamamoto
Journal:  J Pediatr       Date:  1988-04       Impact factor: 4.406

5.  Different karyotypic patterns in early and advanced stage neuroblastomas.

Authors:  Y Kaneko; N Kanda; N Maseki; M Sakurai; Y Tsuchida; T Takeda; I Okabe; M Sakurai
Journal:  Cancer Res       Date:  1987-01-01       Impact factor: 12.701

6.  Deletion of genes on chromosome 1 in endocrine neoplasia.

Authors:  C G Mathew; B A Smith; K Thorpe; Z Wong; N J Royle; A J Jeffreys; B A Ponder
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

7.  Loss of genes on chromosome 22 in medullary thyroid carcinoma and pheochromocytoma.

Authors:  S Takai; H Tateishi; I Nishisho; T Miki; K Motomura; A Miyauchi; M Kato; T Ikeuchi; K Yamamoto; M Okazaki
Journal:  Jpn J Cancer Res       Date:  1987-09

8.  Human neuroblastomas and abnormalities of chromosomes 1 and 17.

Authors:  F Gilbert; M Feder; G Balaban; D Brangman; D K Lurie; R Podolsky; V Rinaldt; N Vinikoor; J Weisband
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

9.  Deletion mapping on the distal third region of chromosome 1p in multiple endocrine neoplasia type IIA.

Authors:  K P Yang; C V Nguyen; S G Castillo; N A Samaan
Journal:  Anticancer Res       Date:  1990 Mar-Apr       Impact factor: 2.480

10.  Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis.

Authors:  B R Oppedal; I Storm-Mathisen; S O Lie; P Brandtzaeg
Journal:  Cancer       Date:  1988-08-15       Impact factor: 6.860

View more
  3 in total

1.  Central neurocytomas with MIB-1 labeling index over 10% showing rapid tumor growth and dissemination.

Authors:  Yoshikazu Ogawa; Takayuki Sugawara; Hirobumi Seki; Tutomu Sakuma
Journal:  J Neurooncol       Date:  2006-03-22       Impact factor: 4.130

2.  Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells.

Authors:  M W Ollert; K David; C Schmitt; A Hauenschild; R Bredehorst; R Erttmann; C W Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

3.  Tumour progression of human neuroblastoma cells tagged with a lacZ marker gene: earliest events at ectopic injection sites.

Authors:  N R Kleinman; K Lewandowska; L A Culp
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.